Mechanisms of idiosyncratic drug reactions: the case of felbamate.
about
Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometriesIdentification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity.CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.New technologies and screening strategies for hepatotoxicity: use of in vitro models.Role of metabolism in drug-induced idiosyncratic hepatotoxicity.Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health.Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism.Animal models of idiosyncratic drug-induced liver injury--current status.Central role of mitochondria in drug-induced liver injury.Metabolic activation in drug-induced liver injury.Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.The generation, detection, and effects of reactive drug metabolites.Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?Non-cytochrome P450-mediated bioactivation and its toxicological relevance.Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame?
P2860
Q33574656-6758C884-B8DD-4DF2-AE90-2D22621EA0C0Q34376979-A332E1F6-6CE5-4559-AF10-DDE4518D740EQ34702576-3D1CF372-5695-4760-A020-1A93D91D26F0Q36086407-06B7FE42-7FEA-44B5-8CE5-E67ACA00D420Q36179528-EBB616CE-AC6A-433E-9BF5-070B81CA324CQ36370381-42643764-E273-4FB7-A432-AD95CAA14849Q36555922-BB3C40A6-7E9F-4B3A-81D2-99D633A19F06Q36662875-59E708A3-E3A4-4FC1-81F8-B6B7EDF224EBQ37391731-C9952F82-846D-4BF8-8069-B4477605FBC2Q37550673-99171019-8F0B-4722-8647-71B7382FB3BAQ37897219-8D95BE75-B1CE-4D50-9DA7-3823422ECBB7Q37926590-2D4170F0-39B8-4C8B-BC66-356ED6574D6CQ37937051-7E6DED79-7940-44BF-8114-5B5113E09CF2Q38008438-44D8F901-45AD-4124-95B4-1D7B5786FE22Q38054629-7A716B15-1A3B-48CA-8BE5-47C2393D9DDEQ38177342-E16C1A95-E86B-4871-BB0B-4E7515147626Q38929936-A89E8AD6-3661-45BD-A254-74F24C900666Q46076879-BAD9BA61-26B5-47C7-917F-DCCEB90B2A39Q53809448-1B5ECC05-C419-46E7-A0AE-57DB90671771
P2860
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@ast
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@en
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@nl
type
label
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@ast
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@en
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@nl
prefLabel
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@ast
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@en
Mechanisms of idiosyncratic drug reactions: the case of felbamate.
@nl
P2093
P1476
Mechanisms of idiosyncratic drug reactions: the case of felbamate
@en
P2093
Charles D Thompson
Christine M Dieckhaus
Timothy L Macdonald
P304
P356
10.1016/S0009-2797(02)00057-1
P577
2002-11-01T00:00:00Z